Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 20/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082868 | 1.00 | STS (0.68) | STSCA1CA2CA9ESR1 | |
| SCHEMBL7083757 | 0.84 | STS (0.49) | STSCA1CA2CA9ESR1 | |
| SCHEMBL7083754 | 0.84 | STS (0.49) | STSCA1CA2CA9ESR1 | |
| SCHEMBL6871662 | 0.82 | STS (0.69) | STSCA1CA2CA9ESR1 | |
| SCHEMBL3384071 | 0.81 | STS (1.00) | STSCA1CA2CA9ESR1 | |
| SCHEMBL3384069 | 0.81 | STS (1.00) | STSCA1CA2CA9ESR1 | |
| SCHEMBL7082645 | 0.80 | SHBG (0.62) | STSESR1ESR2 | |
| SCHEMBL6633748 | 0.78 | STS (0.44) | STSCA1CA2CA9ESR1 | |
| SCHEMBL6633753 | 0.78 | STS (0.44) | STSCA1CA2CA9ESR1 | |
| Emate SCHEMBL6370815 | 0.77 | STS (1.00) | STSCA1CA2CA9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | SCHERING AG (DE) | 2003-05-29 | — | — | US | claimed |
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | SCHERING AG (DE) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100544-A1 | Inhibiting tubulin polymerization; treating prostate and breast cancer | TUBA1C, TUBB1, NR5A1 | STS 399/4885CA1 2920/4885CA2 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.